| Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. | |
| | |
MedLine Citation:
|
PMID: 19856144 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Malignant gliomas--glioblastoma multiforme and anaplastic astrocytoma--are among the most fatal forms of cancer in humans. It has been suggested that hepatocyte growth factor (HGF) is a reliable predictor of glioma malignancy; amounts of HGF are directly related to cellular proliferation, angiogenesis, low apoptotic rate, and poor prognosis (WHO III and IV). We measured the HGF content of cerebrospinal fluid (CSF) from patients with malignant glioma glioblastoma multiforme (WHO IV; n = 14), anaplastic astrocytoma (WHO III; n = 4), and meningioma (WHO I; n = 9), and from control subjects (n = 25), and found a high concentration of HGF in patients with malignant glioma. However, CSF concentrations from glioblastoma multiforme and anaplastic astrocytoma patients were not statistically significantly different (893 +/- 157 vs. 728 +/- 61, respectively; P > 0.01). A negative correlation between HGF and survival was found at five years of follow-up (R = -0.922, R (2) = 0.850, P < 0.001). Also, the HGF concentration in CSF was a reliable means of explaining the highly variable survival of patients with malignant glioma. CSF concentrations of HGF higher than 500 pg/ml were associated with increased mortality whereas values higher than 850 pg/ml were associated with a brief tumor-free period after surgery (9 +/- 0.6 vs. 6 +/- 0.6 months, respectively, P < 0.001). Our findings support the idea that measurement of HGF in CSF could be a useful tool for monitoring the biological activity of malignant glioma. The findings will ultimately need to be confirmed in a much larger study. |
| | |
Authors:
|
Roberto Garcia-Navarrete; Esperanza Garcia; Oscar Arrieta; Julio Sotelo |
Related Documents
:
|
9258924 - Mr diffusion imaging of human intracranial tumours. 11300334 - Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase ... 11940704 - Long-term survival after gene therapy for a recurrent glioblastoma. 2172864 - Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after ra... 11849804 - Postoperative radiotherapy in thymic carcinoma: treatment results and prognostic factors. 3544084 - Randomised study of mopp (mustine, oncovin, procarbazine, prednisone) against lopp (leu... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2009-10-25 |
Journal Detail:
|
Title: Journal of neuro-oncology Volume: 97 ISSN: 1573-7373 ISO Abbreviation: J. Neurooncol. Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-04-22 Completed Date: 2010-07-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8309335 Medline TA: J Neurooncol Country: United States |
Other Details:
|
Languages: eng Pagination: 347-51 Citation Subset: IM |
Affiliation:
|
Neuroimmunology Unit, Instituto Nacional de Neurología y Neurocirugía, Insurgentes Sur 3877, Distrito Federal CP 14269, Mexico. roberto.gns@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Analysis of Variance Brain Neoplasms / cerebrospinal fluid*, diagnosis, mortality* Female Glioblastoma / cerebrospinal fluid*, diagnosis, mortality* Hepatocyte Growth Factor / cerebrospinal fluid* Humans Kaplan-Meiers Estimate Male Middle Aged |
| Chemical | |
Reg. No./Substance:
|
67256-21-7/Hepatocyte Growth Factor |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Inactivation of the proximal NPXY motif impairs early steps in LRP1 biosynthesis.
Next Document: Phospholipase D modulation by ceramide in senescence.